MedTrace Logo

Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection

NCT04315753 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2020-03-20

No results posted yet for this study

Summary

Validation of biomolecular markers in the circulation and radiomic features are the focus of this project.The aim is to assess the role of molecular and cellular biomarkers (exosomes antigens, Circulating tumor cells - CTCs, panel of mutations in circulating free DNA) and radiomic signature, as complementary to assist early detection of lung cancer by LDCT.

Conditions

Interventions

OTHER

LDCT (Low Dose CT)

validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results

Sponsors & Collaborators

  • Ospedale San Raffaele

    collaborator OTHER

  • University of Paris 5 - Rene Descartes

    collaborator OTHER

  • European Institute of Oncology

    collaborator OTHER

  • Istituto Superiore di Sanità

    collaborator OTHER

  • Istituto Clinico Humanitas

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315753 on ClinicalTrials.gov